Understanding HIV Transmission Mechanisms: Microbicides and PrEPJuly 22, 2010 Transcript (.pdf) For more information on this session, including access to speaker presentations, please see the conference Programme-at-a-Glance. Understanding factors and mechanisms, cellular pathways, viral features and immune interaction of mucosal HIV transmission should provide important insight to design prevention methods to interrupt transmission. Animal and human studies aiming at blocking mucosal HIV transmission including microbicides and pre-exposure prophylaxis (PrEP) are ongoing. Outcomes of such studies may reshape the landscape of HIV prevention programmes. One of the most promising prevention technologies currently in trials are microbicides which contain antiretrovirals (also referred to as topical PrEP) and oral antiretroviral PrEP or a combination of both. Results of microbicides/PrEP trials are likely to begin appearing in late 2010 and early 2011. Research and development of novel prevention technologies should take into account ethical considerations and involvement of communities in study design. The session will also address challenges and limitations encountered during clinical trials from a community perspective. Presentations in This Session: Introduction Characteristics of Transmitted Viruses in Acute and Early HIV Infection Oral PrEP During Mucosal SHIV Infection Reduces Viremia, Preserves CD4 Counts, and Raises Potent T Cell Responses Understanding Mucosal Immunity and HIV Transmission: the Way to New Prevention Technologies Exposure of Extracellular and Intracellular Tenofovir and Emtricitabine in Mucosal Tissues After a Single of Fixed-Dose TDF/FTC: Implications for Pre-Exposure HIV Prophylaxis (PrEP) Current and Planned HIV Prevention Trials: Microbicides and PrEP Prevention Research Advocacy: Community Preparedness in HIV Prevention Trials and Use of Existing Prevention Methodologies Conclusions HIV Transmission Mechanisms: Microbicides and PrEP (.mp3)
![]() Safety and Effectiveness of 1% Tenofovir Vaginal Microbicide Gel in South African Women: Results of the CAPRISA 004 Trial This article was provided by Henry J. Kaiser Family Foundation. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before adding your comment, please read TheBody.com's Comment Policy.)
|
|